Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Hallmarks of Cancer: The Next Generation
2011 Standout
EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts
2006 StandoutNobel
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis
2004
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate
2004
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report
2010 StandoutNobel
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
2010
Cellular and molecular mechanisms of fibrosis
2007 Standout
In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
2011
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
PARP inhibitor combination therapy
2016
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children
2006
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING
2004
Indolizidine and quinolizidine alkaloids
2007 Standout
Drug development from marine natural products
2008 Standout
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations
2008
Amino acids: metabolism, functions, and nutrition
2009 Standout
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
2010
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
2008
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
2014 StandoutNobel
Disulfonimide‐Catalyzed Asymmetric Vinylogous and Bisvinylogous Mukaiyama Aldol Reactions
2010 StandoutNobel
Molecular mechanisms of cisplatin resistance
2011 Standout
Antibody therapy of cancer
2012 Standout
Conservation, Variability and the Modeling of Active Protein Kinases
2007 StandoutNobel
Targeting multidrug resistance in cancer
2006 Standout
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
2006
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Systemic sclerosis: a prototypic multisystem fibrotic disorder
2007 Standout
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes
2002
The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
2007 Standout
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
2004
Pancreatic Cancer
2010 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Phosphine-triggered synthesis of functionalized cyclic compounds
2008 Standout
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
Drug interaction studies between paclitaxel (Taxol) and OC144-093 — A new modulator of MDR in cancer chemotherapy
2002
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
2019 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Herb-Drug Interactions
2005 Standout
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
Reversal of experimental pulmonary hypertension by PDGF inhibition
2005
Illuminating signaling network functional biology through quantitative phosphoproteomic mass spectrometry
2008
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Moving from Basic Toward Systems Pharmacodynamic Models
2013
Gastrointestinal toxicities of novel agents in cancer therapy
2009
Indolizidine and quinolizidine alkaloids
2004 Standout
Overview of the Status and Global Strategy for Neonicotinoids
2010 Standout
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
2006
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
2007
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Tumour stem cells and drug resistance
2005 Standout
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
2008 StandoutNobel
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction
2005
Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
2005
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
2003
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
The Many Roles for Fluorine in Medicinal Chemistry
2008 Standout
Mechanisms of drug inhibition of signalling molecules
2006 Nature
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
2007
Non-Smad TGF-β signals
2005 Standout
Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420
2007
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
2001
Do Fukui Function Maxima Relate to Sites of Metabolism? A Critical Case Study
2005
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
2006
Diurnal cycle of sparteine production in Lupinus arcticus
2005
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
2000
Quality of life in chronic lymphocytic leukemia: A neglected issue
2005
Part 14: Pediatric Advanced Life Support
2010 Standout
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
2009
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
2007
Works of John Duan being referenced
Human liver microsomal metabolism of paclitaxel and drug interactions
1998
Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications
2005
Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006
2007
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
2002
Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen
2005
Alkaloid distribution in two species of Lupinus in central British Columbia
1994